Energenesis Biomedical has entered into a joint development agreement with Taiwan Tanabe Seiyaku, the wholly owned subsidiary of Tanabe Pharma Corporation, for ENERGI-F703DFU, Energenesis' investigational topical drug for diabetic foot ulcers (DFU).
Under the agreement, Energenesis and Taiwan Tanabe will collaborate on process technology transfer and CMC activities intended to support a potential NDA for ENERGI-F703DFU in Taiwan.
The parties also plan to advance discussions regarding future manufacturing and commercialisation licenses in Taiwan and selected ASEAN markets, subject to separate definitive agreements and applicable regulatory approvals.
The collaboration brings together Energenesis' proprietary ENERGI drug development platform and late-stage clinical programme with Taiwan Tanabe's local pharmaceutical development, manufacturing and commercial capabilities. The companies expect the partnership to improve execution efficiency for Taiwan registration preparation, reduce downstream commercialisation risk and establish a framework for broader regional market development.
ENERGI-F703DFU is an investigational topical small-molecule gel designed to promote healing of diabetic foot ulcers by modulating cellular energy pathways. The drug candidate is intended to increase intracellular ATP levels at the wound site, support epithelial cell migration and activate intrinsic repair mechanisms.
